


**COVID-19 IMPACT**

This report has been affected by the COVID-19 pandemic. All forecasts and analysis have been revised to reflect the current view including the effect of the pandemic and associated recession.

# RESEARCH REPORT



## GENOMIC CANCER PANEL AND PROFILING MARKETS BY CANCER AND GERMLINE/SOMATIC TYPE WITH SCREENING POTENTIAL MARKET SIZE, CUSTOMIZED FORECASTING/ANALYSIS, AND EXECUTIVE AND CONSULTANT GUIDES 2021-2025



Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

Table of Contents

- i. Cancer Panel Market - Strategic Situation Analysis & COVID Update .....20
- ii. Guide for Executives, Marketing, Sales and Business Development Staff .....23
- iii. Guide for Management Consultants and Investment Advisors .....25
- 1. Introduction and Market Definition .....26
  - 1.1 What are Cancer Gene Panels and Profiling? ..... 27
  - 1.2 The Sequencing Revolution ..... 30
  - 1.3 Market Definition ..... 32
    - 1.3.1 Revenue Market Size ..... 32
  - 1.4 Methodology ..... 33
    - 1.4.1 Authors ..... 33
    - 1.4.2 Sources ..... 34
  - 1.5 A Spending Perspective on Clinical Laboratory Testing ..... 35
    - 1.5.1 An Historical Look at Clinical Testing ..... 35
- 2. Market Overview .....38
  - 2.1 Players in a Dynamic Market ..... 39
    - 2.1.1 Academic Research Lab ..... 40
    - 2.1.2 Diagnostic Test Developer ..... 40
    - 2.1.3 Instrumentation Supplier ..... 40
    - 2.1.4 Distributor and Reagent Supplier ..... 41

2.1.5 Independent Testing Lab.....	41
2.1.6 Public National/regional lab .....	42
2.1.7 Hospital lab .....	42
2.1.8 Physician Office Labs .....	43
2.1.9 Audit Body .....	43
2.1.10 Certification Body.....	43
2.2 Oncogenomics.....	45
2.2.1 Carcinogenesis.....	45
2.2.2 Chromosomes, Genes and Epigenetics.....	47
2.2.2.1 Chromosomes .....	47
2.2.2.2 Genes.....	49
2.2.2.3 Epigenetics .....	52
2.2.3 Cancer Genes.....	53
2.2.4 Germline vs Somatic .....	55
2.2.5 Gene Panels, Single Gene Assays and Multiplexing .....	56
2.2.6 Genomic Profiling.....	57
2.2.7 The Comprehensive Assay .....	58
2.2.8 Changing Clinical Role .....	58
2.2.9 The Cancer Screening Market Opportunity.....	60
2.3 Cancer Management vs. Diagnosis .....	60
2.3.1 The Role of Risk Assessment .....	61
2.3.2 Diagnosis .....	61
2.3.3 Managing .....	61
2.3.4 Monitoring.....	62

- 2.4 Phases of Adoption – Looking into The Future ..... 62
- 2.5 Structure of Industry Plays a Part ..... 63
  - 2.5.1 Hospital Testing Share ..... 63
  - 2.5.2 Economies of Scale ..... 63
    - 2.5.2.1 Hospital vs. Central Lab ..... 64
  - 2.5.3 Physician Office Lab's ..... 65
  - 2.5.4 Physician's and POCT ..... 66
- 3. Market Trends ..... 67
  - 3.1 Factors Driving Growth ..... 68
    - 3.1.1 Level of Care ..... 68
    - 3.1.2 Companion Dx ..... 69
    - 3.1.3 Immuno-oncology ..... 69
    - 3.1.4 Liability ..... 69
    - 3.1.5 Aging Population ..... 69
  - 3.2 Factors Limiting Growth ..... 71
    - 3.2.1 State of knowledge ..... 71
    - 3.2.2 Genetic Blizzard ..... 72
    - 3.2.3 Protocol Resistance ..... 72
    - 3.2.4 Regulation and coverage ..... 72
  - 3.3 Instrumentation and Automation ..... 73
    - 3.3.1 Instruments Key to Market Share ..... 73
    - 3.3.2 Bioinformatics Plays a Role ..... 73
  - 3.4 Diagnostic Technology Development ..... 74
    - 3.4.1 Next Generation Sequencing Fuels a Revolution ..... 75

3.4.2 Single Cell Genomics Changes the Picture ..... 76

3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment ..... 77

3.4.4 CGES Testing, A Brave New World ..... 77

3.4.5 Biochips/Giant magneto resistance based assay ..... 78

4. Cancer Panels & Profiles Recent Developments .....79

4.1 Recent Developments – Importance and How to Use This Section ..... 80

4.1.1 Importance of These Developments ..... 80

4.1.2 How to Use This Section ..... 80

Biocartis Collaborating With GeneproDx, Endpoint Health on Tests for Idylla Platform ..... 80

Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test ..... 82

Metastatic Cancer Markers Identified in Clinical WGS Study ..... 82

Stitch Bio Bets on CRISPR Tech ..... 85

Bayer, LifeLabs Launch Free NTRK Genetic Testing Program ..... 90

Foundation Medicine Liquid Biopsy Gets FDA Approval for Multiple Companion Dx ..... 91

Progress, Challenges in Liquid Biopsy Reimbursement ..... 92

Israeli Startup Curesponse Raises \$6M ..... 96

Invitae, ArcherDX Merge to Advance Precision Oncology Offerings ..... 97

MD Anderson Precision Oncology Decision Support to Use Philips' Informatics Solution ..... 97

NeoGenomics, Lilly Oncology Partner for Thyroid Cancer Testing Program ..... 98

Germline Results Guides Precision Therapy in Advanced Cancer ..... 99

FDA Clears Cancer Genomic Profiling Kit From Personal Genome Diagnostics ..... 104

ArcherDX, Premier Collaborate to Evaluate Genomic Sequencing Assay for Cancers ..... 104

Labs Reporting Cancer Risk Mutations from Tumor Testing ..... 105

Users Begin Integrating Genomics Data for Clinical Decision Support ..... 113

Fujitsu Improves Efficiency in Cancer Genomic Medicine .....	119
Thermo Fisher's automated sequencer to offer same-day, pan-cancer test results .....	120
Universal Genetic Testing for All Breast Cancer Patients.....	121
Exact Sciences buys Genomic Health.....	122
Multi-Gene Liquid Biopsy Breast Cancer Panel.....	124
Thrive to Develop Earlier Detection of Multiple Cancer Types .....	125
New Gene Panel Identifies High Risk Prostate Cancer .....	127
Guardant Health Liquid Biopsy Test to be Covered by EviCore.....	128
Biocept Partnership Offering for Liquid Biopsy Adds Several Key Services .....	129
Natera Commercializes Tumor Whole Exome Sequencing from Plasma .....	130
Inivata Completes £39.8M Series B Funding Round.....	131
Bio-Rad Clinical ddPCR Test, Diagnostic System Get FDA Clearance.....	132
CellMax, Medigen Biotech Partner in Colorectal Cancer Clinical Trials .....	133
Biodesix Acquires Integrated Diagnostics .....	134
Predicine, Kintor Pharmaceuticals Partner on Clinical Trials, CDx.....	134
5. Profiles of Key Players .....	136
Abbott Diagnostics.....	137
AccuraGen Inc.....	139
Acuamark Diagnostics.....	140
Admera Health, LLC.....	141
Agena Bioscience, Inc.....	143
Agilent .....	145
Almac Diagnostics .....	147
Amoy Diagnostics Co., Ltd. ....	148



Anchor Dx .....	149
ANGLE plc .....	150
ApoCell, Inc. ....	152
ArcherDx, Inc. ....	153
Asuragen.....	154
AVIVA Biosciences .....	156
Baylor Miraca Genetics Laboratories .....	157
Beckman Coulter, Inc. ....	158
Becton, Dickinson and Company.....	160
BGI Genomics Co. Ltd .....	162
Bioarray Genetics .....	164
Biocartis .....	165
Biocept, Inc.....	166
Biodesix Inc. ....	167
BioFluidica .....	168
bioMérieux Diagnostics .....	169
Bioneer Corporation.....	171
Bio-Rad Laboratories, Inc.....	173
Bio-Techne .....	175
Bioview .....	177
Blueprint Genetics .....	179
Bolidics.....	180
Boreal Genomics .....	181
Caris Molecular Diagnostics .....	182

CellMax Life.....	183
Cepheid (now Danaher) .....	184
Chronix Biomedical .....	186
Circulogene .....	187
Clinical Genomics .....	188
Cynvenio .....	189
Cytolumina Technologies Corp. ....	190
CytoTrack.....	191
Datar Cancer Genetics Limited.....	192
Diagenode Diagnostics .....	193
Diagnologix LLC.....	194
Enzo Life Sciences, Inc. ....	195
Epic Sciences.....	197
Epigenomics AG.....	198
Eurofins Scientific .....	199
Exosome Diagnostics.....	202
Exosome Sciences.....	204
Fluidigm Corp .....	205
Fluxion Biosciences.....	207
Foundation Medicine.....	208
Freenome .....	209
Fulgent Genetics .....	210
GeneFirst Ltd. ....	211
Genetron Health (Beijing) Co., Ltd.....	212

Genomic Health .....	213
GILUPI Nanomedizin .....	215
Grail, Inc. ....	216
Guardant Health .....	218
HansaBiomed .....	219
HeiScreen .....	220
Helomics.....	222
Horizon Discovery .....	224
iCellate .....	226
Illumina .....	227
Incell Dx.....	229
Inivata.....	230
Invitae Corporation .....	231
Integrated Diagnostics.....	233
Janssen Diagnostics .....	234
Loxo Oncology .....	235
MDNA Life SCIENCES, Inc.....	236
MDx Health .....	237
Menarini Silicon Biosystems .....	239
Millipore Sigma.....	240
Miltenyi Biotec.....	241
miR Scientific .....	242
Molecular MD .....	243
Myriad Genetics/Myriad RBM .....	244

NantHealth, Inc. ....	246
Natera .....	248
NeoGenomics .....	250
New Oncology .....	252
Novogene Bioinformatics Technology Co., Ltd. ....	253
Oncocyte.....	255
OncoDNA.....	256
Oxford Nanopore Technologies.....	257
Perkin Elmer .....	259
Personal Genome Diagnostics.....	261
PrecisionMed .....	262
Promega .....	263
Qiagen Gmbh .....	265
Quidel.....	267
Rarecells SAS.....	269
RareCyte .....	271
Resolution Biosciences, Inc .....	272
Roche Molecular Diagnostics .....	273
Screecell .....	275
Siemens Healthineers .....	276
simfo GmbH .....	278
Singlera Genomics Inc. ....	279
SRI International.....	280
Sysmex Inostics.....	282

Tempus Labs, Inc. ....	283
Thermo Fisher Scientific Inc. ....	284
Thrive Earlier Detection .....	286
Trovagene .....	287
Volition.....	288
6. The Global Market for Cancer Gene Panels and Profiles .....	289
6.1 Global Market Overview by Country .....	290
6.1.1 Table – Global Market by Country .....	290
6.1.2 Chart - Global Market by Country .....	291
6.2 Global Market by Cancer Type - Overview .....	292
6.2.1 Table – Global Market by Cancer Type .....	292
6.2.2 Chart – Global Market by Cancer Type – Base/Final Year Comparison .....	293
6.2.3 Chart – Global Market by Cancer Type – Base Year .....	294
6.2.4 Chart – Global Market by Cancer Type – Final Year.....	295
6.2.5 Chart – Global Market by Cancer Type – Share by Year .....	296
6.2.6 Chart – Global Market by Cancer Type – Segment Growth .....	297
6.3 Global Market Germline & Somatic - Overview .....	298
6.3.1 Table – Global Market Germline & Somatic .....	298
6.3.2 Chart – Global Market Germline & Somatic – Base/Final Year Comparison .....	299
6.3.3 Chart – Global Market Germline & Somatic – Base Year .....	300
6.3.4 Chart – Global Market Germline & Somatic – Final Year.....	301
6.3.5 Chart – Global Market Germline & Somatic – Share by Year.....	302
6.3.6 Chart – Global Market Germline & Somatic – Segment Growth .....	303
7. Global Cancer Gene Panels & Profiles Markets – By Type of Cancer .....	304

7.1 Comprehensive Panels & Profiles .....	305
7.1.1 Table Comprehensive Testing – by Country.....	305
7.1.2 Chart - Comprehensive Testing Growth.....	306
7.2 Breast Cancer Gene Testing.....	307
7.2.1 Table Breast Cancer Gene Testing – by Country.....	307
7.2.2 Chart - Breast Cancer Testing Growth.....	308
7.3 Colorectal Cancer Gene Testing.....	310
7.3.1 Table Colorectal Cancer Gene Testing – by Country.....	310
7.3.2 Chart - Colorectal Cancer Gene Testing Growth.....	311
7.4 Gynecological Cancer Gene Testing .....	312
7.4.1 Table Gynecological Cancer Gene Testing – by Country .....	312
7.4.2 Chart - Gynecological Cancer Gene Testing Growth.....	313
7.5 Blood Cancer Gene Testing .....	314
7.5.1 Table Blood Cancer Gene Testing – by Country .....	314
7.5.2 Chart - Blood Cancer Gene Testing Growth.....	315
7.6 Prostate Cancer Gene Testing.....	316
7.6.1 Table Prostate Cancer Gene Testing – by Country .....	316
7.6.2 Chart - Prostate Cancer Testing Growth .....	317
7.7 Lung Cancer Gene Testing.....	318
7.7.1 Table Lung Cancer Gene Testing – by Country.....	318
7.7.2 Chart - Lung Cancer Gene Testing Growth.....	319
7.8 Other Cancer Gene Testing .....	320
7.8.1 Table Other Cancer Gene Testing – by Country .....	320
7.8.2 Chart - Other Cancer Gene Testing Growth.....	321

8. Global Cancer Gene Testing Markets – Germline and Somatic .....322

    8.1 Global Market Somatic ..... 323

        8.2.1 Table Somatic – by Country ..... 323

        7.2.2 Chart - Somatic Testing Growth ..... 324

    7.3 Global Market Germline ..... 325

        7.3.1 Table Germline – by Country..... 325

        7.3.2 Chart - Germline Testing Growth..... 326

9. Potential Market Opportunity Sizes .....327

    9.1 Potential Cancer Screening by Country: Lung, Breast & Colorectal ..... 329

    9.2 Potential Cancer Screening by Country: Prostate, Other Cancer & All Cancer ..... 331

    9.3 Potential Market Size - Cancer Diagnosis ..... 333

    9.4 Potential Market Size – Therapy Selection ..... 335

Appendices .....337

    I. United States Medicare System: January 2020 Clinical Laboratory Fees Schedule ..... 337

    II. FDA Approved Human Genetic Tests ..... 387

    III. Pharmacogenomic Biomarkers in Drug Labeling ..... 392

## Table of Tables

Table 1 Medicare Clinical Lab Expenditures Actual & Forecast 2014 to 2024 (\$Billion) .....	37
Table 2 Market Players by Type .....	39
Table 3 The Base Pairs.....	50
Table 4 Five Factors Driving Growth .....	68
Table 5 Four Factors Limiting Growth .....	71
Table 6 Key Diagnostic Laboratory Technology Trends .....	74
Table 7 Next Generation Sequencing Technologies – Speed and Cost .....	75
Table 8 - Global Cancer Panel Market by Region.....	290
Table 9 Global Market by Cancer Type .....	292
Table 10 Global Market Germline & Somatic .....	298
Table 11 Comprehensive Testing by Country.....	305
Table 12 Breast Cancer Gene Testing by Country.....	307
Table 13 Colorectal Cancer Gene Testing by Country.....	310
Table 14 Gynecological Cancer Testing by Country .....	312
Table 15 Blood Cancer Gene Testing by Country .....	314
Table 16 Prostate Cancer Gene Testing by Country .....	316
Table 17 Lung Cancer Gene Testing by Country.....	318
Table 18 Other Cancer Gene Testing by Country .....	320
Table 19 Somatic by Country .....	323
Table 20 Germline by Country.....	325
Table 21 Potential Screening Market: Lung, Breast & Colorectal.....	329



Table 22 Potential Screening Market: Prostate, Other & All ..... 331

Table 23 Potential Cancer Diagnosis Market Size ..... 333

Table 24 Potential Cancer Management Market Size ..... 335

Table 25 2020 Laboratory Fee Schedule ..... 337

Table 26 FDA Approved Human Genetic tests ..... 387

Table 27 Pharmacogenomic Biomarkers ..... 392

## Table of Figures

Figure 1 VistSeq Hereditary Cancer Panel.....	29
Figure 2 Medicare Clinical Lab Expenditures 2014 to 2024 (\$Million) .....	36
Figure 3 The Genomic Progression of Cancer.....	46
Figure 4 DNA Strands and Chromosomes .....	47
Figure 5 Karyogram of Human Chromosomes.....	48
Figure 6 Size of Various Genomes .....	51
Figure 7 Germline vs Somatic Mutations.....	55
Figure 8 Comparing Genomic Diagnostic and Traditional Testing .....	59
Figure 9 Percentage of World Population Over 65.....	70
Figure 10 Base Year Country Global Share .....	291
Figure 11 Global Market by Cancer - Base vs. Final Year .....	293
Figure 12 Cancer Panel Market Base Year.....	294
Figure 13 Cancer Panel Market Final Year .....	295
Figure 14 Cancer Type Share by Year .....	296
Figure 15 Cancer Type Segment Growth .....	297
Figure 16 Germline & Somatic - Base vs. Final Year .....	299
Figure 17 Germline & Somatic Market Base Year .....	300
Figure 18 Germline & Somatic Market Final Year.....	301
Figure 19 Germline & Somatic Share by Year .....	302
Figure 20 Germline & Somatic Segment Growth .....	303
Figure 21 Comprehensive Testing Growth.....	306

Figure 22 Breast Cancer Testing Growth..... 308

Figure 23 Colorectal Cancer Gene Testing Growth ..... 311

Figure 24 Gynecological Cancer Testing Growth ..... 313

Figure 25 Blood Cancer Gene Testing Growth ..... 315

Figure 26 Prostate Cancer Gene Testing Growth ..... 317

Figure 27 Lung Cancer Gene Testing Growth..... 319

Figure 28 Other Cancer Gene Testing Growth ..... 321

Figure 29 Somatic Testing Growth ..... 324

Figure 30 Germline Testing Growth ..... 326